Does Priority Health Cover Wegovy?
The verdict
Conditional on most plans
Priority Health's Wegovy coverage is employer-dependent and not publicly published in detail. Weight-loss coverage on commercial plans requires the employer to have purchased the anti-obesity benefit. Michigan Medicaid covers Wegovy as a preferred anti-obesity medication with prior authorization and quantity limits for eligible members age 12 and older, though status should be verified. Medicare covers only the cardiovascular risk reduction indication.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Priority Health using your member ID.
Key facts
BCBS of Michigan ended weight-loss GLP-1 coverage for fully insured large-group plans effective January 1, 2025, citing GLP-1 spend growth from $8 million to nearly $200 million over three years — signaling Michigan-market cost pressure relevant to all Michigan health plans.
BCBS of Michigan, 2024 coverage policy announcement
Michigan Medicaid covers Wegovy as a preferred anti-obesity medication with prior authorization and quantity limits for members age 12 and older — one of 13 states covering GLP-1s for obesity as of January 2026.
KFF, Medicaid Coverage of and Spending on GLP-1s, 2026
Wegovy is FDA-approved for chronic weight management (BMI 30+, or 27+ with a weight-related comorbidity) and for cardiovascular risk reduction in adults with established CVD — it is not a diabetes drug and cannot be routed through a diabetes benefit.
FDA, Wegovy (semaglutide) prescribing information
Medicare vs. commercial coverage
Whether Priority Health covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D cannot cover Wegovy for weight loss by federal statute. For Priority Health Medicare members with established cardiovascular disease who are overweight or obese, the cardiovascular risk reduction indication is coverable under Part D with prior authorization. The $2,100 beneficiary OOP cap applies in 2026. The Medicare GLP-1 Bridge (launching July 1, 2026, through December 31, 2027) provides weight-loss access to Wegovy at a fixed $50 per month copay outside Part D — this does not count toward the deductible, TrOOP, or the $2,100 cap. Bridge eligibility requires provider attestation: BMI 35 or higher; or BMI 30 or higher with heart failure, uncontrolled hypertension, or CKD; or BMI 27 or higher with prediabetes, prior MI, prior stroke, or symptomatic PAD. Members already receiving a Part D-covered GLP-1 are ineligible for the Bridge. Medicare beneficiaries cannot use the NovoCare savings card.
Commercial / Employer
Group & marketplace plans
Priority Health is a Michigan-based plan, and its Wegovy coverage for weight loss is not publicly published at the drug level. For commercial and employer-sponsored members, weight-loss coverage is employer-dependent — the employer must have purchased the anti-obesity benefit. Michigan's insurance market has seen significant cost pressure on weight-loss GLP-1 coverage: BCBS of Michigan ended weight-loss GLP-1 coverage for fully insured large-group plans effective January 1, 2025, signaling a statewide pattern of benefit tightening. ACA/individual plans generally exclude Wegovy for weight loss. Michigan Medicaid covers Wegovy as a preferred anti-obesity medication with prior authorization and quantity limits for members age 12 and older — verify current Michigan Medicaid preferred drug list status. Verify Priority Health commercial coverage on the plan drug-lookup tool and confirm with HR.
The 5 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349 per month (Novo Nordisk published list price for a 28-day supply)
List price with no coverage — before any manufacturer savings card.
With coverage
Commercial cost-share where the employer opted in: not publicly published; varies by plan tier. NovoCare Wegovy Savings Offer: commercially insured members whose plan covers Wegovy may pay as little as $25 per month (max savings $100 per 28-day supply). Michigan Medicaid: nominal cost-share where covered. Medicare CV indication: Part D cost-share depends on tier and benefit phase; $2,100 OOP cap 2026. Medicare Bridge (weight loss, from 7/1/2026): fixed $50 per month outside Part D.
Typical monthly copay once prior authorization is approved.
Bridge program
NovoCare self-pay program: approximately $199 per month for starting doses (0.25/0.5 mg, first two fills through December 31, 2026), then approximately $349 per month for standard doses. Not available to Medicare or Medicaid beneficiaries. From January 1, 2027, Novo Nordisk has announced a list-price reduction to approximately $675 per month; the IRA-negotiated Maximum Fair Price of $274 per 30-day supply also takes effect January 1, 2027.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Actual cost-share varies by plan tier and pharmacy. Confirm with Priority Health member services or the plan drug-lookup tool.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Run Wegovy through the Priority Health drug-lookup tool
Visit the Priority Health member portal and search for Wegovy (semaglutide 2.4 mg) on your specific plan's formulary. Confirm coverage status, tier (if any), and prior-authorization requirements for your particular plan.
- 2
Confirm with HR whether the anti-obesity benefit is included
Because weight-loss coverage is employer-dependent, ask HR directly whether anti-obesity or weight-loss drugs are included in your plan. Michigan's weight-loss GLP-1 coverage has been tightening across employers — do not assume coverage based on the insurer brand alone.
- 3
Ask your prescriber about Bridge eligibility or the CV indication
Medicare members should ask their provider about GLP-1 Bridge eligibility (launching July 1, 2026, at $50/month outside Part D). For members with established cardiovascular disease and overweight or obesity, the cardiovascular risk reduction indication may provide a separate coverage path with prior authorization.
Options if Priority Health won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Michigan Medicaid preferred anti-obesity coverage
Michigan Medicaid covers Wegovy as a preferred anti-obesity medication with prior authorization and quantity limits for members age 12 and older. Verify current preferred drug list status with Priority Health Medicaid or the Michigan DHHS formulary.
Cardiovascular indication (Medicare Part D or commercial)
Wegovy is FDA-approved for cardiovascular risk reduction in adults with established CVD who are overweight or obese. This indication may be coverable under Medicare Part D or certain Priority Health commercial plans with prior authorization.
Medicare GLP-1 Bridge
Launching July 1, 2026, the Bridge provides eligible Medicare beneficiaries weight-loss access to Wegovy at $50 per month through December 31, 2027, outside Part D. Eligibility criteria apply; members already on a Part D-covered GLP-1 are ineligible.
Compounded semaglutide
Compounded semaglutide, available through licensed telehealth platforms, does not require insurance prior authorization. Starting from $49 per month. Compounded semaglutide is not the same medication as Wegovy and has not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Coverage depends on your employer's benefit design. Priority Health does not publicly publish drug-level Wegovy detail — the only reliable way to confirm is to run your plan through the drug-lookup tool and ask HR whether anti-obesity drugs are included. Where the employer purchased the anti-obesity benefit, Wegovy is typically covered with prior authorization. Michigan Medicaid covers Wegovy as a preferred anti-obesity medication with PA for members age 12 and older; verify current status. Medicare covers the CV indication only.
BCBS of Michigan ended weight-loss GLP-1 coverage for fully insured large-group plans effective January 1, 2025 — an explicit, dated exclusion affecting a large portion of Michigan's commercially insured population. Priority Health's commercial coverage is employer-dependent and not publicly published, so the outcome varies by employer benefit design. Members of both plans should verify their specific plan, but the BCBS Michigan exclusion signals the cost pressure that Michigan-market plans are operating under.
Michigan Medicaid covers Wegovy as a preferred anti-obesity medication with prior authorization and quantity limits for members age 12 and older. Wegovy is not a diabetes drug, so it cannot be routed through a diabetes benefit — it must be covered under the state's anti-obesity benefit. Verify current preferred drug list status with Priority Health Medicaid or Michigan DHHS, as formulary coverage may change with budget cycles.
Commercially insured Priority Health members whose plan covers Wegovy may use the NovoCare Wegovy Savings Offer (as little as $25 per month, max savings $100 per 28-day supply). The card is not available to Medicare or Medicaid beneficiaries due to federal anti-kickback rules. It applies only where the plan covers Wegovy — if your Priority Health plan excludes weight-loss drugs, the card cannot be used at standard retail. ACA exchange and state-employee plans are not treated as government programs for this offer.
A prior-authorization denial is a medical-necessity decision — the plan reviewed your case and declined it; you have appeal rights. A benefit exclusion means the drug category is not covered under the plan design at all — no appeal reverses it because it was never in the covered benefit. For Priority Health commercial plans, if your employer excluded weight-loss drugs, that is a benefit exclusion and appeal is not a productive path. Confirm with HR whether the exclusion is at the benefit level or whether a PA could succeed.
Related Articles
Does Network Health Cover Wegovy? 2026 Coverage Guide | Curex
Network Health covers Wegovy only where your employer opted in. Medicare Advantage faces the Part D exclusion. Verify on Network Health's drug-lookup tool.
Read moreDoes BCBS of Arizona Cover Wegovy? 2026 Guide | Curex
BCBS of Arizona covers Wegovy only where your employer opted in; formulary not published. Verify via drug-lookup and confirm with HR first.
Read moreDoes Blue Cross Blue Shield Cover Wegovy? 2026 | Curex
BCBS is 33+ independent affiliates — no single Wegovy answer. Trend favors exclusion in 2025-2026. Find your affiliate and verify your formulary.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Wegovy? | Curex
BCBS Illinois (HCSC) covers Wegovy only where your employer opts in. ACA plans exclude it. Formulary not public — verify on your plan's drug-lookup tool.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes Oscar Health Cover Wegovy? ACA Plans 2026 | Curex
Oscar Health excludes Wegovy on ACA plans. Drug details unpublished — check Oscar drug lookup. NovoCare $25/mo card works on ACA plans if covered.
Read moreWhether or not Priority Health covers Wegovy, there's a path that skips insurance
Priority Health covers Wegovy for weight loss only where the employer opted in, and Michigan's market has been tightening. For patients without a covered route, compounded semaglutide from $49/mo (compounded tirzepatide from $149/mo) is available at Curex — no insurance, no prior authorization. Compounded semaglutide is not the same medication as Wegovy. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Priority Health before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.